Clayton Besaw, University of Central Florida and Matthew Frank, University of Denver

Did the United States just have a coup attempt?

Supporters of President Donald Trump, following his encouragement, stormed the U.S. Capitol building on Jan. 6, disrupting the certification of Joe Biden’s election victory. Waving Trump banners, hundreds of people broke through barricades and smashed windows to enter the building where Congress convenes. One rioter and one police officer died in the clash and several other police officers were hospitalized. Congress went on lockdown.

While violent and shocking, what happened on Jan. 6 wasn’t a coup.

This Trumpist insurrection was election violence, much like the election violence that plagues many fragile democracies.

Elizabeth C. Tippett, University of Oregon

 One of the consequences of the #MeToo movement is a simmering male anxiety that a harmless chat by the water cooler might somehow end in a harassment complaint to HR – or worse.

Korydon Smith, University at Buffalo; Kelly Hayes McAlonie, University at Buffalo, and Rebecca Rotundo, University at Buffalo

While the pandemic has caused thousands of small businesses to temporarily close or shutter for good, the disappearance of the corner coffee shop means more than lost wages.

It also represents a collective loss of creativity.

Researchers have shown how creative thinking can be cultivated by simple habits like exercise, sleep and reading. But another catalyst is unplanned interactions with close friends, casual acquaintances and complete strangers. With the closure of coffee shops – not to mention places like bars, libraries, gyms and museums – these opportunities vanish.

Of course, not all chance meetings result in brilliant ideas. Yet as we bounce from place to place, each brief social encounter plants a small seed that can gel into a new idea or inspiration.

By missing out on chance meetings and observations that nudge our curiosity and jolt “a-ha!” moments, new ideas, big and small, go undiscovered.

 Tony Potts, a 69-year-old retiree, removes his face mask for a temperature check just before receiving his first injection in a phase 3 COVID-19 vaccine clinical trial sponsored by Moderna. Potts is one of 30,000 participants in the Moderna trial.

Christopher Robertson, Boston University and Jeremy Greene, Johns Hopkins University

In coming days, the Food and Drug Administration is likely to authorize new COVID-19 vaccines based on applications submitted by two companies. These authorizations have happened very fast in a process called “emergency use authorizations,” or EUAs.

Does this swift action mean that products are proven safe and effective? Not exactly. But it suggests that they may present a reasonable balance of risks and benefits.

We are a physician and a lawyer, and we also study drug development from the perspectives of history and philosophy. The longer view is helpful to understand the differences between full FDA approval and EUAs.